Ascletis Pharma News More News
Ascletis Pharma Historical Prices
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
Ascletis Pharma Analyst Opinions
- All
- Buy
- Hold
- Sell
Ascletis Pharma Estimates* in HKD
| 2023 | 2024 | |
|---|---|---|
| Revenue | 260 | 371 |
| Dividend | 0.00 | 0.00 |
| Dividend Yield (in %) | - | - |
| EPS | -0.10 | -0.06 |
| P/E Ratio | -29.91 | -46.76 |
| EBIT | -197 | -133 |
| EBITDA | -166 | -120 |
| Net Profit | -108 | -68 |
| Net Profit Adjusted | - | - |
| Pre-Tax Profit | -105 | -44 |
| Net Profit (Adjusted) | - | - |
| EPS (Non-GAAP) ex. SOE | - | - |
| EPS (GAAP) | - | - |
| Gross Income | 366 | 461 |
| Cash Flow from Investing | - | - |
| Cash Flow from Operations | - | - |
| Cash Flow from Financing | - | - |
| Cash Flow per Share | - | - |
| Free Cash Flow | - | - |
| Free Cash Flow per Share | - | - |
| Book Value per Share | 2.48 | 2.33 |
| Net Debt | -2,341 | -2,106 |
| Research & Development Exp. | 129 | 117 |
| Capital Expenditure | - | - |
| Selling, General & Admin. Exp. | - | - |
| Shareholder’s Equity | - | - |
| Total Assets | - | - |
|
Previous Quarter ending 12/31/22 |
Current Quarter | Next Quarter |
Current Year ending 12/31/23 |
Next Year ending 12/31/24 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 1 | - | - | 4 | 4 |
| Average Estimate | 0.045 HKD | - | - | -0.096 HKD | -0.061 HKD |
| Year Ago | - | - | - | - | -0.096 HKD |
| Publish Date | 3/20/2023 | - | - | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 1 | - | - | 4 | 4 |
| Average Estimate | 240 HKD | - | - | 260 HKD | 371 HKD |
| Year Ago | - | - | - | - | 260 HKD |
| Publish Date | 3/20/2023 | - | - | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Ascletis Pharma Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2021 | Ascletis Pharma Inc. Registered Shs Unitary 144A-Reg S | - | - | HKD |
| 2020 | Ascletis Pharma Inc. Registered Shs Unitary 144A-Reg S | - | - | HKD |
| 2019 | Ascletis Pharma Inc. Registered Shs Unitary 144A-Reg S | - | - | HKD |
| 2018 | Ascletis Pharma Inc. Registered Shs Unitary 144A-Reg S | - | - | HKD |
| 2017 | Ascletis Pharma Inc. Registered Shs Unitary 144A-Reg S | - | - | HKD |
| 2016 | Ascletis Pharma Inc. Registered Shs Unitary 144A-Reg S | - | - | HKD |
*Yield of the Respective Date
Ascletis Pharma Inc. Registered Shs Unitary 144A-Reg S Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 0.045 HKD | Q4 2022 Earnings Release | 03/20/2023 |
| Earnings Report | - | Q2 2023 Earnings Release | 09/01/2023 |
| Earnings Report | - | Q4 2023 Earnings Release | 03/18/2024 |
| Earnings Report | - | Q2 2024 Earnings Release | 08/30/2024 |
Ascletis Pharma Profile
Ascletis Pharma, Inc. operates as biotechnology firm to test the waters. The company was founded by Jinzi J. Wu and is headquartered in Hangzhou, China.
Ascletis Pharma Shareholder
| Owner | in % |
|---|---|
| Jinzi J. Wu, PhD | 47.53 |
| Freefloat | 19.28 |
| Yang Dan | 9.70 |
| Judy Hejingdao Wu | 7.62 |
| CBC Group (Singapore) Pte. Ltd. | 5.90 |
| Ying Yang He | 5.85 |
| Wu Jinzi Jayson Family | 4.12 |
| Vanguard Emerging Markets Stock Index Fund | 0.56 |
| Vanguard Total International Stock Index Fund | 0.54 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.